Values First Advisors Inc. Reduces Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Values First Advisors Inc. lowered its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 4.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 26,524 shares of the medical instruments supplier’s stock after selling 1,216 shares during the quarter. LeMaitre Vascular comprises about 1.3% of Values First Advisors Inc.’s holdings, making the stock its 13th biggest holding. Values First Advisors Inc. owned approximately 0.12% of LeMaitre Vascular worth $2,444,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of LMAT. NBC Securities Inc. lifted its position in LeMaitre Vascular by 73.2% in the third quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 183 shares during the last quarter. GAMMA Investing LLC lifted its position in LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after buying an additional 188 shares during the last quarter. KBC Group NV lifted its position in LeMaitre Vascular by 58.4% in the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 410 shares during the last quarter. Empowered Funds LLC acquired a new position in LeMaitre Vascular in the fourth quarter valued at about $150,000. Finally, SG Americas Securities LLC acquired a new position in LeMaitre Vascular in the fourth quarter valued at about $158,000. Institutional investors and hedge funds own 84.64% of the company’s stock.

Analyst Upgrades and Downgrades

LMAT has been the topic of a number of recent analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $93.00 target price (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target on the stock. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Finally, Barrington Research increased their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

Insider Buying and Selling

In related news, Director Bridget A. Ross sold 3,750 shares of the company’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the sale, the director now directly owns 2,278 shares in the company, valued at approximately $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Stock Performance

LMAT stock opened at $96.94 on Wednesday. The company’s 50 day moving average price is $96.43 and its 200 day moving average price is $93.37. LeMaitre Vascular, Inc. has a fifty-two week low of $58.66 and a fifty-two week high of $109.58. The firm has a market capitalization of $2.18 billion, a price-to-earnings ratio of 52.97, a PEG ratio of 2.19 and a beta of 0.96.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.